Abstract
Background Guidelines on COVID-19 management are developed as we learn from this pandemic. However, most research has been done on hospitalised patients and the impact of the disease on non-hospitalised and their role in transmission are not yet well understood.
The COVID HOME study conducts research among COVID-19 patients and their family members who were not hospitalised during acute disease, to guide patient care and inform public health guidelines for infection prevention and control in the community and household.
Methods An ongoing prospective longitudinal observational study of COVID-19 outpatients was established in March 2020 in the Netherlands. Laboratory confirmed SARS-CoV-2 infected individuals of all ages that did not merit hospitalisation, and their household (HH) members, were enrolled after written informed consent. Enrolled participants were visited at home within 48 hours after initial diagnosis, and then weekly on days 7, 14 and 21 to obtain clinical data, a blood sample for biochemical parameters/cytokines and serological determination; and a nasopharyngeal/throat swab plus urine, stool and sperm or vaginal secretion (if consenting) to test for SARS-CoV-2 by RT-PCR (viral shedding) and for viral culturing. Weekly nasopharyngeal/throat swabs and stool samples, plus a blood sample on days 0 and 21 were also taken from HH members to determine whether and when they became infected. All participants were invited to continue follow-up at 3-, 6-, 12- and 18-months post-infection to assess long-term sequelae and immunological status.
Preliminary Results A total of 256 participants belonging to 103 HH were included of which, 190 (74.2%) were positive for SARS-CoV-2 infection. Most individuals (183/190, 96.3%) developed mild to moderate disease. At the time of writing, all participants had reached the 3 and 6 month time-points of the long-term follow-up, while approximately 78% reached 12 month and 23% the 18 month time-point. Preliminary analysis showed that 43% (52/121) positive individuals reported having complaints at 3 months post-infection, while 42.7% (61/143) had complaints at 6 months.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AT, grant 10430012010023, Netherlands Organisation for Health Research and Development (ZonMw), https://www.zonmw.nl/nl/over-zonmw/ AWF, 101016167, European Union’s Horizon 2020 research and innovation programme, https://web-staging.orchestra-cohort.eu/ The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Date 7 July 2020 METc number METc 2020/158 NEW Title Prospective cohort study of non-hospitalised COVID-19 patients: determining length of isolation and patient clinical development at home (COVID-HOME study). Old title: UMCG COVID-19 patient follow-up study: Understanding SARS-Cov2 infection and patient clinical development. UMCG RR number 202000198 The Medical Ethics Review Board of the University Medical Center Groningen (METc UMCG) has discussed the amendment regarding the above mentioned protocol. The committee considered whether or not the proposed changes lead to a different outcome. Based on the submitted documents the METc UMCG concludes that the amended protocol does not change the fact that the trial does not fall within the scope of the WMO. It is still not a clinical research with human subjects as meant in the Medical Research Involving Human Subjects Act (WMO). Kind regards, the Medical Ethics Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding The project received funding from the Netherlands Organisation for Health Research and Development (ZonMw) [1], grant 10430012010023, and as partner of the ORCHESTRA project [2] which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016167. The views expressed in this publication are the sole responsibility of the author and the Commission is not responsible for any use that may be made of the information it contains. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests The authors have declared that no competing interests exist.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
